Stockscreener 앱 받기
11.82
11.40%
1.21
시장 영업 전:
12.19
0.37
+3.13%
전일 마감가:
$10.61
열려 있는:
$11.21
하루 거래량:
1.13M
Relative Volume:
1.11
시가총액:
$526.72M
수익:
$110.24M
순이익/손실:
$-66.44M
주가수익비율:
-7.8221
EPS:
-1.5111
순현금흐름:
$-61.12M
1주 성능:
+24.95%
1개월 성능:
-3.11%
6개월 성능:
-62.38%
1년 성능:
-23.79%
1일 변동 폭
$11.01
$12.42
1주일 범위
$9.03
$12.42
52주 변동 폭
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
명칭
Beta Bionics Inc
전화
949-427-7785
주소
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
11.82 | 472.80M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | UBS | Buy |
| 2026-01-27 | 개시 | TD Cowen | Hold |
| 2026-01-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-10-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-06-12 | 개시 | Lake Street | Buy |
| 2025-05-30 | 개시 | Goldman | Neutral |
| 2025-05-30 | 개시 | Wolfe Research | Outperform |
| 2025-02-24 | 개시 | BofA Securities | Buy |
| 2025-02-24 | 개시 | Lake Street | Buy |
| 2025-02-24 | 개시 | Leerink Partners | Outperform |
| 2025-02-24 | 개시 | Piper Sandler | Overweight |
| 2025-02-24 | 개시 | Stifel | Buy |
| 2025-02-20 | 개시 | Ladenburg Thalmann | Neutral |
| 2025-02-20 | 개시 | Robert W. Baird | Neutral |
모두보기
Beta Bionics Inc 주식(BBNX)의 최신 뉴스
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics | 8-K: Current report - Moomoo
Beta Bionics (NASDAQ: BBNX) investors approve directors and auditor - Stock Titan
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development - Sahm
Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027 - Moomoo
[144] Beta Bionics, Inc. SEC Filing - Stock Titan
Beta Bionics says Mint commercialization expected by end-Q2 2027, subject to FDA clearance - TradingView
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX) - Stock Titan
No-recharge insulin patch pump targets 2027 launch pending FDA clearance - Stock Titan
BBNX Maintains by B of A Securities -- Price Target Lowered to $11.00 - GuruFocus
Beta Bionics Price Target Cut to $11.00/Share From $23.00 by B of A Securities - Moomoo
Beta Bionics, Inc. Stock 12‑Month Price Target Cut to $19.18, Implies 103% Upside - TradingView
BofA Adjusts Price Target on Beta Bionics to $11 From $23 - Moomoo
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Cuts Target Price to $11 - Moomoo
BBNX Forecast — Price Target — Prediction for 2027 - TradingView
Beta Bionics | SCHEDULE 13G/A: Others - Moomoo
Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics - Stock Titan
RTW Investments reports 2.0M-share stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans - Yahoo Finance
BBNX: Mint patch pump launch set for end of 2027, with pharmacy channel driving growth - TradingView
Farallon and Zone Holdings disclose ownership in Beta Bionics (BBNX) — 13G/A - Stock Titan
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation - Yahoo Finance
Number of shareholders of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Soleus group files 9.8% stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a Potential 93% Upside in Medical Devices - DirectorsTalk Interviews
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $16 to $20 - Moomoo
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock? - MSN
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99 - MSN
Midday Stock Roundup: Tech stocks rally - Orange County Business Journal
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates - MSN
Beta Bionics to Present at the Bank of America Securities Health Care Conference - The Manila Times
Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% - MSN
BBNX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
BBNX (Beta Bionics Inc.) posts narrower Q4 2025 loss than consensus estimates, sending shares up more than six percent.Analyst Recommended Stocks - Xã Thanh Hà
Lake Street reiterates Buy on Beta Bionics stock on Q1 beat By Investing.com - Investing.com Australia
Beta Bionics Inc (BBNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.41%
자본화:
|
볼륨(24시간):